Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis.
Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis.
复制标题
DOI：
10.3390/jcm5030038
复制
发表时间：
2016-03-16
影响因子：
3.9
通讯作者：
Bloomston PM
中科院分区：
文献类型：
--
作者：
Kitano M;Bloomston PM
microRNAs（miRNAs）是一类非编码小分子RNA，通过阻断靶mRNA的翻译或诱导靶mRNA的降解来调控基因表达。miRNAs在多种生物学和病理学过程中发挥重要作用，包括肝纤维化的发展。肝星状细胞（hepatic stellate cells，HSC）在肝纤维化的发生发展中起着重要作用，miRNAs对HSC的活化、增殖、胶原生成、迁移和凋亡具有复杂的调控作用。活化的HSC中存在多种差异表达的miRNAs，本文就miRNAs参与肝纤维化的研究进展作一综述。基于这一综述，miRNAs可能作为诊断肝脏疾病的生物标志物，以及疾病进展的标志物。最重要的是，失调的miRNAs可能被新疗法靶向治疗和逆转肝纤维化的进展。
microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by either blocking translation or inducing degradation of target mRNA. miRNAs play essential roles in diverse biological and pathological processes, including development of hepatic fibrosis. Hepatic stellate cells (HSCs) play a central role in development of hepatic fibrosis and there are intricate regulatory effects of miRNAs on their activation, proliferation, collagen production, migration, and apoptosis. There are multiple differentially expressed miRNAs in activated HSCs, and in this review we aim to summarize current data on miRNAs that participate in the development of hepatic fibrosis. Based on this review, miRNAs may serve as biomarkers for diagnosis of liver disease, as well as markers of disease progression. Most importantly, dysregulated miRNAs may potentially be targeted by novel therapies to treat and reverse progression of hepatic fibrosis.